In a country where advanced diagnostics are often a luxury, a Bengaluru startup is betting that the same gene-editing technology that won a Nobel Prize can be made cheap and simple enough for a rural clinic. CrisprBits, founded in 2020, is building a suite of CRISPR-based tools, but its immediate focus is on a platform called PathCrisp: a rapid, point-of-need diagnostic system designed to detect diseases like sickle cell anemia and typhoid [PERPLEXITY SONAR PRO BRIEF]. The company’s recent $3 million pre-Series A, led by Spectrum Impact, values the firm at $12 million and is earmarked to scale manufacturing for commercial rollout [Indian Startup Times, 2025].
A Platform Built on Three Pillars
CrisprBits is structured as a platform-first company, an approach that spreads its CRISPR expertise across three distinct but connected product lines.
- PathCrisp: The Diagnostic Wedge. This is the commercial spearhead. It’s a molecular diagnostic system using CRISPR to identify specific genetic markers for infectious diseases and genetic disorders [PERPLEXITY SONAR PRO BRIEF].
- EdiCrisp: The Industrial Play. This platform applies CRISPR gene-editing tools to optimize organisms for industrial processes, such as biofuel production [Express Healthcare, 2025].
- CurieCrisp: The Therapeutic Horizon. This pillar aims at developing CRISPR-based therapies to cure genetic disorders [PERPLEXITY SONAR PRO BRIEF].
The Team and Its Traction
CrisprBits was founded by five alumni from BITS Pilani. Co-founder Vijay Chandru, also listed as Chief Scientific Officer, is the co-founder of Strand Life Sciences [Forbes, 2011]. Another co-founder, Sunil Arora, brings a public-sector profile from his tenure as India’s Chief Election Commissioner [Bloomberg, 2019]. The team has grown to 13 individuals [Inc42].
Commercial traction is beginning to materialize. A significant validation came in the form of a partnership with Molbio Diagnostics, a major player in Indian point-of-care testing [Digital Health News]. The company has also been incubated at C-CAMP, a government-backed biotech incubator [Crunchbase].
The Regulatory and Commercial Path Ahead
For any diagnostic claiming clinical use, regulatory clearance is the gatekeeper. CrisprBits has not yet publicized submissions to India’s Central Drugs Standard Control Organization (CDSCO). The $3 million in new capital is a meaningful war chest, but the company will need to demonstrate that PathCrisp can achieve volume production at its promised low cost points. Furthermore, the diagnostic market is competitive; established players like Molbio and Mylab have significant market share with PCR-based systems. CrisprBits’ differentiation hinges on CRISPR’s potential for faster, simpler, and cheaper tests, a claim that must now be proven at scale in real-world settings.